A new Transparency Market Research report states that the global transfection technology market was valued at US$386.4 mn in 2012 and is poised to reach US$768.2 mn by 2019, logging a CAGR of 9.70% from 2013 to 2019. The title of the report is “Transfection Technology Market – Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 – 2019.”

Transfection is a type of process in which genetic materials including double stranded RNA and DNA are introduced into mammalian cells by non-viral means. The introduction of DNA into cells starts the production or expression of proteins; cells use their own machinery during this. When RNA is transfected, it acts on the cytoplasm and helps down-regulate protein expression by blocking translation.

Transfection technology helps cells in the regulation of gene therapy, protein metabolism, and mutation of cancer cells by impacting the nuclear genes. Transfection technology is majorly utilized in applications such as therapeutic delivery, protein production, and bio-medical research. Biomedical research is further segmented into cancer research, transgenic models, cell-based microarrays for drug delivery and development, and gene and protein expression studies.

Request PDF Sample of Transfection Technology Market Report @ www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1001

According to the report, the increasing obesity and the rising occurrence of cancers of the breast, lung, and prostate globally are amongst the top factors stimulating the growth of the market for transfection technology. In addition, the rising incidence of cardiovascular diseases such as ischemic heart disease and arrhythmias and the increasing production of mass protein are also amongst the chief factors augmenting the growth of the market for transfection technology.

On the other hand, as per the report, the cytotoxic impacts and technological complications associated with the use of instrument-based and virus-based methods utilized in transfection technology may inhibit the development of the market to some extent in forthcoming years.

On the basis of method, the report segments the transfection technology market into reagent-based, virus-based, and instrument-based methods. Reagent-based methods are further sub-segmented into calcium phosphate, lipid mediated transfection (lipfection), DEAE-dextran, catonic polymers, magnetic beads, and activated dendrimers. On the other hand, instrument-based methods are further segmented into biolistic technology, electroporation, laserfection, and microinjection.

Amongst the main segments, reagent-based transfection technology is witnessing exponential development due to it being a simpler and cost-effective method for carrying out transfection. On the other hand, instrument-based transfection technology is also gaining demand owing to this technology being more accurate and less time consuming.

By geography, the report segments the market into Europe, North America, Asia Pacific, and Rest of the World (RoW). Amongst these, in 2012, North America led the market and held a share of more than 45% owing to the increasing initiatives taken by the governments of North American nations. In addition, the rising awareness amongst individuals on the various applications of transfection technology has also positively impacted the growth of the North America transfection technology market.

Enquiry for Discount on “Transfection Technology Market” Report @ www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=1001

Europe trailed North America and constituted the second-largest share in the market in the same year. This was owing to the increasing drug development initiatives and the use of nanomedicine in diagnostics within this region. On the other hand, Asia Pacific is poised to experience the swiftest growth rate of over 10% in the forecast period owing to the use of biopharmaceuticals in drug development and discovery here.

The key players dominant in the market are Lonza Group Ltd, Life Technologies Corporation, Polypus Transfection S.A, Mirus Bio LLC, and Promega Corporation, among others.

Source link